Vasca Launches LifeSite Hemodialysis System Following 510(k) Clearance
This article was originally published in The Gray Sheet
Executive Summary
LifeSite developer Vasca, Inc. launched the hemodialysis access system on Aug. 28, immediately following FDA clearance.
You may also be interested in...
LifeSite Class Action Suit Draws On November FDA Warning Letter
Allegations that Vasca failed to warn the healthcare community about risks associated with its LifeSite hemodialysis access system are among charges in a class action lawsuit that relies on an FDA warning letter to the firm
LifeSite Class Action Suit Draws On November FDA Warning Letter
Allegations that Vasca failed to warn the healthcare community about risks associated with its LifeSite hemodialysis access system are among charges in a class action lawsuit that relies on an FDA warning letter to the firm
Vasca's Vascular Access Device 510(k) Data Show Zero Infection Rate
Infection rates using Vasca's LifeSite vascular access implant fell to zero after the firm's conversion to exclusive use of isopropyl alcohol as the pre-dialysis and post-dialysis antimicrobial sterilizing solution.